<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="287">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03790709</url>
  </required_header>
  <id_info>
    <org_study_id>ANAVEX2-73-AD-004</org_study_id>
    <nct_id>NCT03790709</nct_id>
  </id_info>
  <brief_title>ANAVEX2-73 for Treatment of Early Alzheimer's Disease</brief_title>
  <official_title>A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anavex Life Sciences Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anavex Australia Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anavex Germany GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anavex Canada Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Anavex Life Sciences Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function&#xD;
      after 48 weeks of daily treatment. Additional outcome measures include refined measures of&#xD;
      sleep, behavioral and psychological symptoms typically observed in AD, changes in daily&#xD;
      functioning of participants and changes in caregiver burden, as well as changes in quality of&#xD;
      life measures of both, patients and caregivers during treatment with ANAVEX2-73.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and&#xD;
      function after 48 weeks of daily treatment. Additional outcome measures include refined&#xD;
      measures of sleep, behavioral and psychological symptoms typically observed in AD, changes in&#xD;
      daily functioning of participants and changes in caregiver burden, as well as changes in&#xD;
      quality of life measures of both, patients and caregivers during treatment with ANAVEX2-73.&#xD;
      In addition, safety assessments, pharmacokinetic (PK) assessments and collections of CSF and&#xD;
      blood markers of AD pathophysiology before and after treatment will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 3, 2018</start_date>
  <completion_date type="Actual">June 30, 2022</completion_date>
  <primary_completion_date type="Actual">June 30, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized 1:1:1 to two different ANAVEX2-73 doses or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>There will be blinding procedures for this study. Capsules will be indistinguishable from active ingridient containing capsules.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>ADAS-Cog (Alzheimer Disease Assessment Scale-Cognition)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Reduction in cognitive decline assessed from baseline over 48 weeks with ANAVEX2-73 compared to placebo using the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADCS-ADL (Activities of Daily Living)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Reduction in decline of the ability to perform daily activities assessed from baseline over 48 weeks with ANAVEX2-73 compared to placebo using the Activities of Daily Living Scale (ADCS-ADL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CDR-SB (Clinical Dementia Rating Scale Sum of Boxes)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Reduction in cognitive decline assessed from baseline over 48 weeks with ANAVEX2-73 compared with placebo using the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>48 weeks</time_frame>
    <description>Assess the safety and tolerability of ANAVEX2-73 compared to placebo</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with change of brain volume assessed by MRI</measure>
    <time_frame>48 weeks</time_frame>
    <description>To evaluate the effect of ANAVEX2-73 on structural and Arterial Spin Labeling (ASL) MRI scan assessments characteristic for AD pathophysiology compared to placebo over a 48-week treatment duration</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood assessment</measure>
    <time_frame>48 weeks</time_frame>
    <description>Blood assessment from baseline and compared to placebo at +48 weeks: Abeta40, Abeta42, T-tau, NFL, YKL-40, BACE1 concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>CSF assessment</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in CSF parameters (Abeta40, Abeta42, T-tau, P-tau, NFL, YKL-40, neurogranin, BACE1 concentration) characteristic for AD pathophysiology from baseline and compared to placebo at&#xD;
+48 weekstreatment differences within subgroups will be performed</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with pre-specified genetic variants</measure>
    <time_frame>48 weeks</time_frame>
    <description>AD relevant pre-specified genetic variants will be assessed. Statistical testing of treatment differences within subgroups will be performed</description>
  </other_outcome>
  <other_outcome>
    <measure>RSCAQ sleep score</measure>
    <time_frame>Weeks 0, 4, 12, 24, 36, and 48</time_frame>
    <description>To evaluate whether ANAVEX2-73 improves sleep continuity as assessed on a serial basis (weeks 0, 4, 12, 24, 36, and 48) with a questionnaire that assess reported sleep continuity (RSCAQ)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">509</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>High dose ANAVEX2-73</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose active once daily orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid dose ANAVEX2-73</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid dose active once daily orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dose once daily orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose ANAVEX2-73</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>High dose ANAVEX2-73</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mid dose ANAVEX2-73</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Mid dose ANAVEX2-73</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Placebo oral capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 60 to 85 years, inclusive, with a NIA-AA diagnosis of mild cognitive&#xD;
             impairment (MCI) due to AD or early stage mild dementia due to AD. AD diagnosis should&#xD;
             be made by an appropriately qualified medical specialist and AD pathology should be&#xD;
             confirmed by either:&#xD;
&#xD;
               1. Historical records of amyloid CSF assessment or&#xD;
&#xD;
               2. Historical records of amyloid PET scan or&#xD;
&#xD;
               3. If neither historical records are available, then AD pathological diagnosis&#xD;
                  confirmation should be offered at screening:&#xD;
&#xD;
             i. CSF collection or ii. Amyloid PET iii. Past medical records of MRI or CT are&#xD;
             optional.&#xD;
&#xD;
          -  Mini Mental State Examination (MMSE) score between 20-28, inclusive.&#xD;
&#xD;
          -  Free Recall score ≤17 or Total Recall score &lt;40 on the Free and Cued Selective&#xD;
             Reminding Test (FCSRT).&#xD;
&#xD;
          -  Participants are either outpatients, or residents of an assisted-living facility.&#xD;
             Participant has a designated study partner, who spends at least 10hrs per week with&#xD;
             the participant, in order that assessments e.g. carer burden instruments are completed&#xD;
             with true knowledge of the participant.&#xD;
&#xD;
          -  No suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale&#xD;
             (C-SSRS) in the past 3 months (i.e. active suicidal thought(s) with intent but without&#xD;
             specific plan, or active suicidal thought(s) with plan and intent) OR suicidal&#xD;
             behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted&#xD;
             attempt, or preparatory acts or behavior).&#xD;
&#xD;
          -  Confirmation from the participant that, if of childbearing potential is not pregnant&#xD;
             through urine pregnancy testing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have a progressive medical or neurological condition that in the opinion&#xD;
             of the investigator would interfere with the conduct of the study. Exception: If&#xD;
             diagnosed with seizures, must be on stable anti-seizure medication for at least 3&#xD;
             months prior to screening.&#xD;
&#xD;
          -  Current clinically significant systemic illness that is likely to result in&#xD;
             deterioration of the patient's condition or affect the patient's safety during the&#xD;
             study.&#xD;
&#xD;
          -  History or clinically evident stroke or clinically significant carotid or&#xD;
             vertebrobasilar stenosis or plaque.&#xD;
&#xD;
          -  History of neurologic (e.g. stroke, traumatic brain injury) or psychiatric condition&#xD;
             that the investigator deems may interfere with interpretability of data.&#xD;
&#xD;
          -  History of untreated thyroid disorder, Type 1 diabetes, and insulin dependent or&#xD;
             uncontrolled Type II diabetes, as determined by the investigator (e.g.&#xD;
             non-insulin-controlled Type II diabetes, whose HbA1c value is higher than 8.0%).&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 30.&#xD;
&#xD;
          -  History of clinical hepatic dysfunction.&#xD;
&#xD;
          -  Current symptomatic and unstable/uncontrolled gastrointestinal, hepatic, renal,&#xD;
             respiratory, cardiovascular, metabolic, immunological, hematological or hormonal&#xD;
             disorders.&#xD;
&#xD;
          -  Indication of liver disease, defined by serum levels of ALT (SGPT), AST (SGOT), or&#xD;
             alkaline phosphatase above 3x upper limit of normal (ULN) as determined during&#xD;
             screening.&#xD;
&#xD;
          -  Significant history of drug addiction (with the exception of nicotine dependence) or&#xD;
             abuse (including alcohol, as defined in DSM-V or in the opinion of the investigator)&#xD;
             within the last two years prior to informed consent, or a positive urine drug screen&#xD;
             for cocaine, opioid, phencyclidine (PCP), amphetamine or marijuana at screening.&#xD;
             Prescription medication yielding a positive drug screen are acceptable except for&#xD;
             tricyclic antidepressants (e.g. Amitriptyline, Amoxapine, Desipramine, (Norpramin)&#xD;
             Doxepin, Imipramine (Tofranil), Nortriptyline (Pamelor), Protriptyline (Vivactil),&#xD;
             Trimipramine (Surmontil)).&#xD;
&#xD;
          -  Clinically significant infection within the last 30 days prior screening (e.g.,&#xD;
             chronic persistent or acute infection, urinary tract infections (UTI)).&#xD;
&#xD;
          -  Treatment with immunosuppressive medications (e.g., systemic corticosteroids) within&#xD;
             the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for&#xD;
             asthma are permitted) or chemotherapeutic agents for malignancy within the last 3&#xD;
             years.&#xD;
&#xD;
          -  Myocardial infarction within the last year.&#xD;
&#xD;
          -  History of cancer within the last 3 years, with the exception of basal cell carcinoma&#xD;
             and non-metastatic squamous cell carcinoma of the skin and prostate cancer with&#xD;
             currently normal PSA.&#xD;
&#xD;
          -  Other clinically significant abnormality on physical, neurological, laboratory, or&#xD;
             electrocardiogram (ECG) examination (e.g., atrial fibrillation) that could compromise&#xD;
             the study or be detrimental to the participant.&#xD;
&#xD;
          -  Hemoglobin &lt; 11 g/dL.&#xD;
&#xD;
          -  Have any contraindication to MRI scanning, including cardiac pacemaker/defibrillator,&#xD;
             ferromagnetic metal implants (e.g., in skull and cardiac devices or severe&#xD;
             claustrophobia).&#xD;
&#xD;
          -  Smoking &gt; 1 pack of cigarettes per day (as assessed for the 30 days prior to&#xD;
             screening).&#xD;
&#xD;
          -  Alcohol use of more than 2 drinks per day.&#xD;
&#xD;
          -  Current use of over-the-counter (OTC) supplements or nutraceuticals unless they are on&#xD;
             stable dose for at least 3 months prior to screening and are documented in the eCRF.&#xD;
&#xD;
          -  Use of over the counter (OTC) or prescription medication for sleep on 2 or more&#xD;
             occasions per week.&#xD;
&#xD;
          -  Being treated with psychoactive medications on a stable dose for less than 3 month.&#xD;
&#xD;
          -  Any prior exposure to ANAVEX2-73.&#xD;
&#xD;
          -  Individuals enrolled in previous AD clinical trial involving an investigational drug&#xD;
             treatment less than 3 months ago (longer than 3 month ago allowed).&#xD;
&#xD;
          -  Any known hypersensitivity to any of the excipients contained in the study drug&#xD;
             formulation.&#xD;
&#xD;
          -  Any other criteria (such as a clinically significant screening blood test result),&#xD;
             which in the opinion of the Investigator causes the participant not to qualify for the&#xD;
             study.&#xD;
&#xD;
          -  Evidence of cerebrovascular dementia with a Hachinski score of 4 or more.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Central Coast Neurosciences Research</name>
      <address>
        <city>Central Coast</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hornsby (Northern Sydney Health)</name>
      <address>
        <city>Hornsby</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KaRa MINDS</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent Hospital Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Memory Disorders Clinic</name>
      <address>
        <city>Southport</city>
        <state>Quennsland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Adelaide Hospital (RAH) and The Queen Elizabeth Hospital (TQEH)</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penninsula Therapeutic and Research Group</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geelong Private Medical Centre</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delmont Private Hospital</name>
      <address>
        <city>Glen Iris</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammond Care</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Alfred Psychiatry Research Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital (RMH)</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McCusker</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthy Brain Aging Labs Uni of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Island Health Authority</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>True North Clinical Research</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>True North Clinical Research</name>
      <address>
        <city>Kentville</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkwood Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bruyere Continuing Care</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawartha Centre</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Crest Health Sciences</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Memory Program</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ulm, Memory Clinic</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayreuth Clinic, Hohe Warte Hospital</name>
      <address>
        <city>Bayreuth</city>
        <state>Bavaria</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technical University of Munich, School of Medicine</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Institute of Mental Health</name>
      <address>
        <city>Mannheim</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goettingen University Medicine, Clinic for Psychiatry and Psychotherapy</name>
      <address>
        <city>Göttingen</city>
        <state>Lower Saxony</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Bonn</name>
      <address>
        <city>Bonn</city>
        <state>North Rhine-Westphalia</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Psychiatry and Psychotherapy</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite University Medicine</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Research Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Research Center</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Research Center</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Teesside</city>
        <state>County Teesside</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgow Memory Clinic</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognition Health</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Barnsley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognition Health</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Cannock</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognition Health</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognition Health</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Health NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>December 24, 2018</study_first_submitted>
  <study_first_submitted_qc>December 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2019</study_first_posted>
  <last_update_submitted>July 12, 2022</last_update_submitted>
  <last_update_submitted_qc>July 12, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

